Niowave is a privately-held nuclear science and radiopharmaceutical company that operates one of the few commercial-scale facilities in the United States capable of producing medical radioisotopes used in cancer imaging and therapy. The company is investing $75M in a new radioisotope production facility to secure domestic supply of critical isotopes (including actinium-225 and copper-67) used in next-generation radiopharmaceuticals.
Company Info
Funding & Investor Relations
None publicly disclosed; private radiopharmaceutical isotope producer with state and federal contract backing.
Upcoming Milestones & Key Dates
Construction and commissioning of new $75M radioisotope production facility
Commercial production ramp of Ac-225 and Cu-67 to meet radiopharma partner demand
Clinical Development Pipeline
Recent News
Niowave is investing $75M in a new radioisotope production facility to secure domestic supply of medical isotopes, while CDMO CordenPharma announced an acquisition of peptide specialist AmbioPharm.
Leadership Team
Chief Executive Officer
Careers & Job Openings